Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

306 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Characteristics of triple-negative breast cancer.
de Ruijter TC, Veeck J, de Hoon JP, van Engeland M, Tjan-Heijnen VC. de Ruijter TC, et al. J Cancer Res Clin Oncol. 2011 Feb;137(2):183-92. doi: 10.1007/s00432-010-0957-x. Epub 2010 Nov 11. J Cancer Res Clin Oncol. 2011. PMID: 21069385 Free PMC article. Review.
Taxane resistance in breast cancer: a closed HER2 circuit?
de Hoon JP, Veeck J, Vriens BE, Calon TG, van Engeland M, Tjan-Heijnen VC. de Hoon JP, et al. Biochim Biophys Acta. 2012 Apr;1825(2):197-206. doi: 10.1016/j.bbcan.2012.01.001. Epub 2012 Jan 18. Biochim Biophys Acta. 2012. PMID: 22280939 Review.
Primary granulocyte colony-stimulating factor prophylaxis during the first two cycles only or throughout all chemotherapy cycles in patients with breast cancer at risk for febrile neutropenia.
Aarts MJ, Peters FP, Mandigers CM, Dercksen MW, Stouthard JM, Nortier HJ, van Laarhoven HW, van Warmerdam LJ, van de Wouw AJ, Jacobs EM, Mattijssen V, van der Rijt CC, Smilde TJ, van der Velden AW, Temizkan M, Batman E, Muller EW, van Gastel SM, Borm GF, Tjan-Heijnen VC. Aarts MJ, et al. J Clin Oncol. 2013 Dec 1;31(34):4290-6. doi: 10.1200/JCO.2012.44.6229. Epub 2013 Apr 29. J Clin Oncol. 2013. PMID: 23630211 Clinical Trial.
Doxorubicin/cyclophosphamide with concurrent versus sequential docetaxel as neoadjuvant treatment in patients with breast cancer.
Vriens BE, Aarts MJ, de Vries B, van Gastel SM, Wals J, Smilde TJ, van Warmerdam LJ, de Boer M, van Spronsen DJ, Borm GF, Tjan-Heijnen VC; Breast Cancer Trialists' Group of the Netherlands (BOOG). Vriens BE, et al. Eur J Cancer. 2013 Oct;49(15):3102-10. doi: 10.1016/j.ejca.2013.06.012. Epub 2013 Jul 10. Eur J Cancer. 2013. PMID: 23850450 Clinical Trial.
Cost effectiveness of primary pegfilgrastim prophylaxis in patients with breast cancer at risk of febrile neutropenia.
Aarts MJ, Grutters JP, Peters FP, Mandigers CM, Dercksen MW, Stouthard JM, Nortier HJ, van Laarhoven HW, van Warmerdam LJ, van de Wouw AJ, Jacobs EM, Mattijssen V, van der Rijt CC, Smilde TJ, van der Velden AW, Temizkan M, Batman E, Muller EW, van Gastel SM, Joore MA, Borm GF, Tjan-Heijnen VC. Aarts MJ, et al. J Clin Oncol. 2013 Dec 1;31(34):4283-9. doi: 10.1200/JCO.2012.48.3644. Epub 2013 Oct 28. J Clin Oncol. 2013. PMID: 24166522 Clinical Trial.
Ultrasound is at least as good as magnetic resonance imaging in predicting tumour size post-neoadjuvant chemotherapy in breast cancer.
Vriens BE, de Vries B, Lobbes MB, van Gastel SM, van den Berkmortel FW, Smilde TJ, van Warmerdam LJ, de Boer M, van Spronsen DJ, Smidt ML, Peer PG, Aarts MJ, Tjan-Heijnen VC; INTENS Study Group. Vriens BE, et al. Eur J Cancer. 2016 Jan;52:67-76. doi: 10.1016/j.ejca.2015.10.010. Epub 2015 Nov 30. Eur J Cancer. 2016. PMID: 26650831 Clinical Trial.
306 results